ANN ARBOR, Mich. – Women who are having bothersome hot flashes and are looking for a non-estrogen based treatment may be eligible to participate in a research study at St. Joseph Mercy Hospital in Ann Arbor. The study will help determine which dose of Pregabilin, a new generation compound, is more helpful in lessening or stopping hot flashes in women. Previous studies have shown this medication to be effective in treating hot flashes.

“Hot flashes are experienced by many women, those with a history of breast cancer and those concerned about the increased risk for breast cancer. Many of these women do not wish to take estrogen therapy due to concerns about breast cancer,” explained Dr. Philip Stella, medical director, St. Joseph Mercy Cancer Care Center. “We hope the research will help us find a better alternative in reducing and eliminating hot flashes.”

North Central Cancer Treatment Group is sponsoring this study out of the Mayo Clinic in Rochester, MN. The Michigan Cancer Research Consortium Community Clinical Oncology Program is offering this study. St. Joseph Mercy Hospital - Ann Arbor is the leading research institution of the Michigan Cancer Research Consortium Community Clinical Oncology Program and participates in more than 100 cancer treatment and prevention trials.

For more information about this study or other cancer treatment and prevention trials, please call Saint Joseph Mercy Cancer Care Center at 734-712-5658 or toll-free 877-590-5995.